Tempest Therapeutics Inc

Change company Symbol lookup

Select an option...

TPST Tempest Therapeutics Inc

AHI Advanced Health Intelligence Ltd

OTLK Outlook Therapeutics Inc

PBHC Pathfinder Bancorp Inc (MARYLAND)

CMA Comerica Inc

IART Integra Lifesciences Holdings Corp

ARKW.SO ARK Next Generation Internet ETF

AGNC Agnc Investment Corp

HCA HCA Healthcare Inc

LGHL Lion Group Holding Ltd

Go

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.